ACR and tuberculosis: Nanoparticles (NPs) have been used for antigen transport along with their adjuvant characteristics and a new TB vaccine called Nano-FP1 has recently been created using yellow carnauba wax NPs coated with a fusion protein containing three Mtb antigens (Acr, Ag85B and HBHA), which has had good results in the preclinical phase (Hart et al. 2018).mRNA technology has progressed over the years and a leap forward was made during the COVID-19 pandemic; the time is thus right for using this technology for developing a new and effective TB vaccine.